Electromed, Inc. (ELMD)

In the past six months, Electromed, Inc. experienced an all-time high of $35.56 on January 30, 2025, followed by a decline to around $18. The company reported record quarterly revenues of $16.3 million for Q2 FY2025, with operating income at $2.5 million and net income at $2 million. Q4 FY2025 earnings reported revenue increasing to $17.4 million and diluted earnings per share reaching $0.25. On September 9, 2025, the Board authorized the repurchase of up to $10.0 million of common stock. Insider selling activity has been observed. As of October 22, 2025, the stock price was $24.81.

Electromed, Inc. experiences demand seasonality for its products and services. Historical data indicates that for October, the bias leans long, with the next statistically strong window culminating around November 15, 2025.

Electromed, Inc. is a medical device company specializing in airway clearance therapy, operating in the Healthcare sector, specifically in the Medical Devices and Biotechnology industries. Its primary product is the SmartVest Airway Clearance System, which uses High Frequency Chest Wall Oscillation (HFCWO) technology to help patients clear mucus from their lungs. The product portfolio includes the SmartVest SQL System, SmartVest Clearway System, and SmartVest Connect. Electromed also markets Single Patient Use (SPU) SmartVest and SmartVest Wrap products. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.

Electromed, Inc. primarily operates in the United States, utilizing a direct sales channel and agreements with Home Medical Equipment (HME) distributors. The company also has an international presence, with approximately 1% of its net revenues in both fiscal 2022 and 2023 derived from sales outside the U.S. Internationally, Electromed sells its products primarily through independent distributors specializing in respiratory products. The company is strategically expanding into acute care settings and select international regions.

Electromed, Inc. has generally maintained a positive media sentiment in the past year. The company emphasizes a commitment to customer service and support as key strategies for growth and patient satisfaction. There is no readily available information indicating specific product recalls, controversies, or widespread negative customer reviews that have significantly impacted Electromed's brand reputation in the past year.

Electromed has a significant portion of its ownership held by institutional shareholders and insiders. Institutional shareholders own 46.17% and Electromed insiders own 102.18%. Major institutional holders include The Vanguard Group, Inc., and BlackRock, Inc. Major individual and insider owners include Red Oak Partners LLC, George H. Winn and Thomas M. Hagedorn.